Compared with the controls, the end of network for AML patients was pointed from IL-1β to IL-1R and from NLRP3 to NF-κB, which indicates that NLRP3 inflammasome may act through IL-1β or NF-κB in AML leukemia cells. The gene discussed is IL1B; the disease is leukemia.